Taysha Gene Therapies Announces Completion of Dosing in REVEAL Trial

What Happened
Taysha Gene Therapies, Inc. (TSHA) filed a Current Report on Form 8-K on June 22, 2026 (Items 7.01 and 8.01) announcing that dosing is complete in the REVEAL pivotal trial evaluating TSHA-102 for Rett syndrome. The company also reported longer‑term clinical data from Part A of the REVEAL Phase 1/2 trials and made a corporate presentation available to discuss the clinical and regulatory updates.

Key Details

• Filing date: June 22, 2026; disclosures made under Regulation FD (Item 7.01) and Other Events (Item 8.01).
• Program: TSHA-102 for Rett syndrome — completion of dosing in the REVEAL pivotal trial.
• Data: Longer‑term clinical data from Part A of the REVEAL Phase 1/2 trials were reported (details provided in the press release and presentation).
• Documents: Press release attached as Exhibit 99.1 and the clinical/regulatory presentation attached as Exhibit 99.2 to the Form 8-K.

Why It Matters
Completion of dosing in a pivotal trial is a key operational milestone that moves the TSHA-102 program closer to potential regulatory review; the release of longer‑term Part A data gives investors updated clinical information to assess safety and efficacy trends. The press release and presentation provide the company’s official clinical and regulatory updates; investors should review those exhibits for specifics on outcomes, endpoints, and next steps.